• Age ≥ 1 year (including cut-off value), gender is not limited

• Expected survival time ≥ 3 months

• Karnofsky score (\> 16 years) or Lansky score (≤ 16 years) \> 60 points

• Meet the clinical diagnostic criteria and be diagnosed as recurrent / refractory neuroblastoma. For first-line standard treatment, please refer to the consensus of experts in the diagnosis and treatment of Pediatric Neuroblastoma (Chinese Journal of Pediatric surgery, Volume 36, No. 1, 2015), the guidelines for the diagnosis and treatment of Pediatric Neuroblastoma of 2019 by the Health Commission, and the consensus of experts in the diagnosis and treatment of Pediatric Neuroblastoma (CCCG-NB-2021 Program) (Chinese Journal of Pediatric surgery, Volume 43, No. 7, 2022)

‣ Recurrence is defined as the determination of recurrence after remission after at least first-line standard treatment.

⁃ Refractory is defined as a person who is not in remission after at least 4 cycles of chemotherapy (≥ 2 chemotherapeutic drugs, including alkylating agents and platinum)

• The tumor tissue samples of the subjects were stained by immunohistochemistry (IHC) to show that the expression intensity of B7-H3 on the surface of tumor cell membranes was 1+ or above, and the proportion of positive staining of tumor cell membranes was ≥1%

• At least one measurable lesion defined by RECISTv1.1 criteria, and at least one lesion that can be irradiated (except bone marrow)

• Subjects with lesions only in the bone marrow may also be enrolled (without irradiation)

• Liver and kidney function, cardiopulmonary function must meet the following requirements:

‣ Total bilirubin ≤ 3 × ULN;ALT and AST ≤ 5 × ULN

⁃ Creatinine≤2 ULN

⁃ Left ventricular ejection fraction ≥ 50%

⁃ Blood oxygen saturation ≥ 92%

• Patients and/or their guardians understand the trial and have signed informed consent